AstraZeneca PLC (AZN) PE Ratio: 27.45
Is AstraZeneca PLC’s P/E ratio high or low?
AstraZeneca PLC's P/E ratio of 27.45 is 57% below its 5-year average of 64.16, near the low end of its 5-year range (25.83–486.11).
As of Friday, June 12, 2026. 7.72% below its 12-month average of 29.75.
PE Ratio (27.45) = Close Price ($182.28) / Diluted TTM EPS ($6.64)
AZN PE Ratio Chart
AZN Average PE Ratio Chart
AZN Current vs Average PE Ratio Chart
AZN PE Ratio Metrics
PE RATIO
27.45
PE RATIO AVG TTM
29.75
PE RATIO AVG 3Y
32.92
PE RATIO AVG 5Y
64.16
PE RATIO AVG 10Y
53.20
PE RATIO AVG 15Y
45.37
PE RATIO AVG 20Y
36.54
CURRENT VS TTM AVG
-7.72%
CURRENT VS 3Y AVG
-16.61%
CURRENT VS 5Y AVG
-57.22%
CURRENT VS 10Y AVG
-48.41%
CURRENT VS 15Y AVG
-39.50%
CURRENT VS 20Y AVG
-24.87%
AZN Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 27.45 | 29.75 | 32.92 | 64.16 |
| Merck & Co., Inc. (MRK) | $298.29B | 34.02 | 15.88 | 94.38 | 65.32 |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 30.63 | 17.96 | 24.48 | 25.25 |
| Amgen Inc. (AMGN) | $191.09B | 24.64 | 25.05 | 29.62 | 26.37 |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 26.15 | 29.21 | 32.53 | 31.18 |
| AbbVie Inc. (ABBV) | $397.12B | 110.22 | 116.44 | 75.58 | 55.76 |
| Gilead Sciences, Inc. (GILD) | $156.28B | 17.15 | 21.32 | 157.32 | 110.39 |
| Abbott Laboratories (ABT) | $156.15B | 24.97 | 19.33 | 27.88 | 28.19 |
| Pfizer Inc. (PFE) | $149.18B | 19.98 | 16.37 | 22.39 | 18.18 |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 50.05 | 65.83 | 75.01 | 71.82 |
P/E vs. its own history
At 27.4, P/E is in its normal range, sitting higher than 47% of its 20-year history.
20-year low
5.8
median
28.8
20-year high
486.1
P/E Comparison
Trailing P/E
27.4
Forward P/E
15.6
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$182.28
Forward EPS (Est.)
$11.66
Forward P/E
15.63
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
AstraZeneca PLC PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC PE Ratio FAQ
- What is the P/E ratio for AstraZeneca PLC (AZN)?
- The P/E ratio for AZN stock is 27.45.
- Is AstraZeneca PLC's P/E ratio high or low?
- AstraZeneca PLC's P/E ratio of 27.45 is 57% below its 5-year average of 64.16, near the low end of its 5-year range (25.83–486.11).
- What is the TTM average P/E ratio for AstraZeneca PLC (AZN)?
- The TTM average P/E ratio for AZN stock is 29.75.
- What is the 3Y average P/E ratio for AstraZeneca PLC (AZN)?
- The 3Y average P/E ratio for AZN stock is 32.92.
- What is the 5Y average P/E ratio for AstraZeneca PLC (AZN)?
- The 5Y average P/E ratio for AZN stock is 64.16.
- What is the 10Y average P/E ratio for AstraZeneca PLC (AZN)?
- The 10Y average P/E ratio for AZN stock is 53.20.
- What is the 15Y average P/E ratio for AstraZeneca PLC (AZN)?
- The 15Y average P/E ratio for AZN stock is 45.37.
- What is the 20Y average P/E ratio for AstraZeneca PLC (AZN)?
- The 20Y average P/E ratio for AZN stock is 36.54.
AstraZeneca PLC PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-11 | 27.45 |
| 2026-06-10 | 26.95 |
| 2026-06-09 | 27.63 |
| 2026-06-08 | 27.34 |
| 2026-06-05 | 28.00 |
| 2026-06-04 | 27.38 |
| 2026-06-03 | 26.55 |
| 2026-06-02 | 26.72 |
| 2026-06-01 | 27.06 |
| 2026-05-29 | 27.96 |
| 2026-05-28 | 27.91 |
| 2026-05-27 | 27.96 |
| 2026-05-26 | 28.19 |
| 2026-05-22 | 28.17 |
| 2026-05-21 | 28.58 |
| 2026-05-20 | 28.23 |
| 2026-05-19 | 27.81 |
| 2026-05-18 | 27.70 |
| 2026-05-15 | 27.35 |
| 2026-05-14 | 27.86 |
| 2026-05-13 | 28.27 |
| 2026-05-12 | 27.79 |
| 2026-05-11 | 27.39 |
| 2026-05-08 | 27.54 |
| 2026-05-07 | 27.49 |
| 2026-05-06 | 27.85 |
| 2026-05-05 | 27.30 |
| 2026-05-04 | 27.63 |
| 2026-05-01 | 27.82 |
| 2026-04-30 | 28.22 |
| 2026-04-29 | 27.89 |
| 2026-04-28 | 28.54 |
| 2026-04-27 | 28.67 |
| 2026-04-24 | 29.01 |
| 2026-04-23 | 29.40 |
| 2026-04-22 | 29.79 |
| 2026-04-21 | 29.94 |
| 2026-04-20 | 30.69 |
| 2026-04-17 | 31.31 |
| 2026-04-16 | 30.65 |
| 2026-04-15 | 30.77 |
| 2026-04-14 | 31.25 |
| 2026-04-13 | 30.92 |
| 2026-04-10 | 31.20 |
| 2026-04-09 | 31.34 |
| 2026-04-08 | 31.23 |
| 2026-04-07 | 30.70 |
| 2026-04-06 | 31.01 |
| 2026-04-02 | 31.11 |
| 2026-04-01 | 30.69 |
| 2026-03-31 | 30.16 |
| 2026-03-30 | 29.65 |
| 2026-03-27 | 28.81 |
| 2026-03-26 | 28.04 |
| 2026-03-25 | 28.61 |
| 2026-03-24 | 28.41 |
| 2026-03-23 | 28.15 |
| 2026-03-20 | 28.07 |
| 2026-03-19 | 28.89 |
| 2026-03-18 | 28.81 |
| 2026-03-17 | 29.25 |
| 2026-03-16 | 29.36 |
| 2026-03-13 | 29.04 |
| 2026-03-12 | 29.43 |
| 2026-03-11 | 29.56 |
| 2026-03-10 | 29.81 |
| 2026-03-09 | 29.81 |
| 2026-03-06 | 29.70 |
| 2026-03-05 | 30.20 |
| 2026-03-04 | 30.81 |
| 2026-03-03 | 30.85 |
| 2026-03-02 | 31.15 |
| 2026-02-27 | 31.87 |
| 2026-02-26 | 31.19 |
| 2026-02-25 | 31.47 |
| 2026-02-24 | 31.59 |
| 2026-02-23 | 34.04 |
| 2026-02-20 | 33.92 |
| 2026-02-19 | 34.65 |
| 2026-02-18 | 34.66 |
| 2026-02-17 | 34.80 |
| 2026-02-13 | 34.14 |
| 2026-02-12 | 33.97 |
| 2026-02-11 | 34.01 |
| 2026-02-10 | 32.08 |
| 2026-02-09 | 31.23 |
| 2026-02-06 | 32.06 |
| 2026-02-05 | 31.09 |
| 2026-02-04 | 31.14 |
| 2026-02-03 | 30.62 |
| 2026-02-02 | 31.30 |
| 2026-01-30 | 31.08 |
| 2026-01-29 | 30.43 |
| 2026-01-28 | 31.20 |
| 2026-01-27 | 31.24 |
| 2026-01-26 | 29.74 |
| 2026-01-23 | 29.49 |
| 2026-01-22 | 29.82 |
| 2026-01-21 | 29.07 |
| 2026-01-20 | 30.43 |
| 2026-01-16 | 31.75 |
| 2026-01-15 | 31.37 |
| 2026-01-14 | 31.60 |
| 2026-01-13 | 31.34 |
| 2026-01-12 | 30.81 |
| 2026-01-09 | 31.73 |
| 2026-01-08 | 31.31 |
| 2026-01-07 | 31.69 |
| 2026-01-06 | 31.64 |
| 2026-01-05 | 29.74 |
| 2026-01-02 | 30.35 |
| 2025-12-31 | 29.15 |
| 2025-12-30 | 30.04 |
| 2025-12-29 | 31.07 |
| 2025-12-26 | 30.11 |
| 2025-12-24 | 30.96 |
| 2025-12-23 | 30.40 |
| 2025-12-22 | 30.02 |
| 2025-12-19 | 30.10 |
| 2025-12-18 | 29.99 |
| 2025-12-17 | 30.69 |
| 2025-12-16 | 30.35 |
| 2025-12-15 | 30.54 |
| 2025-12-12 | 29.84 |
| 2025-12-11 | 30.00 |
| 2025-12-10 | 30.22 |
| 2025-12-09 | 29.75 |
| 2025-12-08 | 30.06 |
| 2025-12-05 | 29.82 |
| 2025-12-04 | 29.91 |
| 2025-12-03 | 30.45 |
| 2025-12-02 | 29.75 |
| 2025-12-01 | 29.96 |
| 2025-11-28 | 30.52 |
| 2025-11-26 | 31.31 |
| 2025-11-25 | 31.18 |
| 2025-11-24 | 30.35 |
| 2025-11-21 | 30.33 |
| 2025-11-20 | 29.54 |
| 2025-11-19 | 29.87 |
| 2025-11-18 | 29.10 |
| 2025-11-17 | 29.11 |
| 2025-11-14 | 29.04 |
| 2025-11-13 | 29.49 |
| 2025-11-12 | 29.18 |
| 2025-11-11 | 29.10 |
| 2025-11-10 | 29.05 |
| 2025-11-07 | 27.60 |
| 2025-11-06 | 28.07 |
| 2025-11-05 | 30.51 |
| 2025-11-04 | 31.06 |
| 2025-11-03 | 30.43 |
| 2025-10-31 | 30.98 |
| 2025-10-30 | 30.95 |
| 2025-10-29 | 30.77 |
| 2025-10-28 | 31.12 |
| 2025-10-27 | 30.83 |
| 2025-10-24 | 30.78 |
| 2025-10-23 | 31.62 |
| 2025-10-22 | 31.36 |
| 2025-10-21 | 31.63 |
| 2025-10-20 | 31.39 |
| 2025-10-17 | 32.12 |
| 2025-10-16 | 31.79 |
| 2025-10-15 | 31.59 |
| 2025-10-14 | 31.79 |
| 2025-10-13 | 31.77 |
| 2025-10-10 | 31.83 |
| 2025-10-09 | 31.93 |
| 2025-10-08 | 32.35 |
| 2025-10-07 | 31.95 |
| 2025-10-06 | 32.39 |
| 2025-10-03 | 32.05 |
| 2025-10-02 | 30.95 |
| 2025-10-01 | 30.56 |
| 2025-09-30 | 28.10 |
| 2025-09-29 | 27.46 |
| 2025-09-26 | 27.47 |
| 2025-09-25 | 28.15 |
| 2025-09-24 | 28.02 |
| 2025-09-23 | 28.33 |
| 2025-09-22 | 29.48 |
| 2025-09-19 | 29.02 |
| 2025-09-18 | 28.83 |
| 2025-09-17 | 29.33 |
| 2025-09-16 | 28.76 |
| 2025-09-15 | 29.06 |
| 2025-09-12 | 29.99 |
| 2025-09-11 | 30.45 |
| 2025-09-10 | 30.10 |
| 2025-09-09 | 30.18 |
| 2025-09-08 | 30.66 |
| 2025-09-05 | 30.92 |
| 2025-09-04 | 30.45 |
| 2025-09-03 | 30.50 |
| 2025-09-02 | 30.20 |
| 2025-08-29 | 30.29 |
| 2025-08-28 | 29.74 |
| 2025-08-27 | 30.20 |
| 2025-08-26 | 30.13 |
| 2025-08-25 | 30.64 |
| 2025-08-22 | 29.53 |
| 2025-08-21 | 30.25 |
| 2025-08-20 | 29.66 |
| 2025-08-19 | 29.90 |
| 2025-08-18 | 30.16 |
| 2025-08-15 | 29.23 |
| 2025-08-14 | 29.28 |
| 2025-08-13 | 29.00 |
| 2025-08-12 | 27.87 |
| 2025-08-11 | 27.47 |
| 2025-08-08 | 26.65 |
| 2025-08-07 | 27.68 |
| 2025-08-06 | 27.95 |
| 2025-08-05 | 28.25 |
| 2025-08-04 | 28.26 |
| 2025-08-01 | 27.73 |
| 2025-07-31 | 27.70 |
| 2025-07-30 | 29.26 |
| 2025-07-29 | 28.29 |
| 2025-07-28 | 28.88 |
| 2025-07-25 | 29.12 |
| 2025-07-24 | 29.44 |
| 2025-07-23 | 29.52 |
| 2025-07-22 | 28.44 |
| 2025-07-21 | 28.00 |
| 2025-07-18 | 27.57 |
| 2025-07-17 | 27.76 |
| 2025-07-16 | 28.46 |
| 2025-07-15 | 28.14 |
| 2025-07-14 | 28.69 |
| 2025-07-11 | 28.11 |
| 2025-07-10 | 28.78 |
| 2025-07-09 | 28.34 |
| 2025-07-08 | 28.09 |
| 2025-07-07 | 28.58 |
| 2025-07-03 | 28.19 |
| 2025-07-02 | 28.83 |
| 2025-07-01 | 28.00 |
| 2025-06-30 | 28.01 |
| 2025-06-27 | 27.69 |
| 2025-06-26 | 28.04 |
| 2025-06-25 | 29.30 |
| 2025-06-24 | 28.27 |
| 2025-06-23 | 28.46 |
| 2025-06-20 | 27.99 |
| 2025-06-18 | 28.78 |
| 2025-06-17 | 28.25 |
| 2025-06-16 | 29.73 |
| 2025-06-13 | 29.67 |
| 2025-06-12 | 30.08 |
| 2025-06-11 | 29.70 |
| 2025-06-10 | 29.38 |
| 2025-06-09 | 29.36 |
| 2025-06-06 | 28.92 |
| 2025-06-05 | 28.61 |
| 2025-06-04 | 29.18 |
| 2025-06-03 | 28.55 |
| 2025-06-02 | 28.56 |
| 2025-05-30 | 28.36 |
Showing the most recent 260 of 4,906 data points. The chart above shows the full history.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot